Deforche K - Search Results

1

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.

Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vézinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, Vandamme AM. Snoeck J, et al. Among authors: deforche k. Antimicrob Agents Chemother. 2006 Feb;50(2):694-701. doi: 10.1128/AAC.50.2.694-701.2006. Antimicrob Agents Chemother. 2006. PMID: 16436728 Free PMC article.

2

Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G.

Abecasis AB, Deforche K, Snoeck J, Bacheler LT, McKenna P, Carvalho AP, Gomes P, Camacho RJ, Vandamme AM. Abecasis AB, et al. Among authors: deforche k. AIDS. 2005 Nov 4;19(16):1799-806. doi: 10.1097/01.aids.0000188422.95162.b7. AIDS. 2005. PMID: 16227787

3

A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes.

Van Laethem K, Schrooten Y, Dedecker S, Van Heeswijck L, Deforche K, Van Wijngaerden E, Van Ranst M, Vandamme AM. Van Laethem K, et al. Among authors: deforche k. J Virol Methods. 2006 Mar;132(1-2):181-6. doi: 10.1016/j.jviromet.2005.10.008. Epub 2005 Nov 4. J Virol Methods. 2006. PMID: 16271771

4

Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.

Gonzalez LM, Santos AF, Abecasis AB, Van Laethem K, Soares EA, Deforche K, Tanuri A, Camacho R, Vandamme AM, Soares MA. Gonzalez LM, et al. Among authors: deforche k. J Antimicrob Chemother. 2008 Jun;61(6):1201-4. doi: 10.1093/jac/dkn099. Epub 2008 Mar 20. J Antimicrob Chemother. 2008. PMID: 18356151

5

Bayesian network analyses of resistance pathways against efavirenz and nevirapine.

Deforche K, Camacho RJ, Grossman Z, Soares MA, Van Laethem K, Katzenstein DA, Harrigan PR, Kantor R, Shafer R, Vandamme AM; non-B Workgroup. Deforche K, et al. AIDS. 2008 Oct 18;22(16):2107-15. doi: 10.1097/QAD.0b013e32830fe940. AIDS. 2008. PMID: 18832874 Free PMC article.

6

The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, Peres S, Carvalho AP, Mansinho K, Vandamme AM, Camacho R. Vercauteren J, et al. Among authors: deforche k. Retrovirology. 2008 Feb 1;5:12. doi: 10.1186/1742-4690-5-12. Retrovirology. 2008. PMID: 18241328 Free PMC article.

7

Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.

Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM; EuroSIDA Study Group. Deforche K, et al. Antivir Ther. 2008;13(3):399-407. Antivir Ther. 2008. PMID: 18572753

8

The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.

Theys K, Vercauteren J, Abecasis AB, Libin P, Deforche K, Vandamme AM, Camacho R. Theys K, et al. Among authors: deforche k. Infect Genet Evol. 2009 Jul;9(4):683-8. doi: 10.1016/j.meegid.2008.10.013. Epub 2008 Nov 6. Infect Genet Evol. 2009. PMID: 19038365

9

Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.

Theys K, Deforche K, Beheydt G, Moreau Y, van Laethem K, Lemey P, Camacho RJ, Rhee SY, Shafer RW, Van Wijngaerden E, Vandamme AM. Theys K, et al. Among authors: deforche k. BMC Bioinformatics. 2010 Aug 3;11:409. doi: 10.1186/1471-2105-11-409. BMC Bioinformatics. 2010. PMID: 20682040 Free PMC article.

10

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.

Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho RJ, Van Laethem K, Pironti A, Zazzi M, Sönnerborg A, Incardona F, De Luca A, Torti C, Ruiz L, Van de Vijver DA, Shafer RW, Bruzzone B, Van Wijngaerden E, Vandamme AM; Virolab and EuResist Projects. Sangeda RZ, et al. Among authors: deforche k. Infect Genet Evol. 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21. Infect Genet Evol. 2013. PMID: 23523594 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page